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In this chapter, taking a life cycle and both civil society and
medically oriented approach, we will discuss the contribution of
the hypertensive disorders of pregnancy (HDPs) to maternal,
perinatal and newborn mortality and morbidity. Here we review
various interventions and approaches to preventing deaths due
to HDPs and discuss effectiveness, resource needs and long-term
sustainability of the different approaches. Societal approaches,
addressing sustainable development goals (SDGs) 2.2 (malnu-
trition), 3.7 (access to sexual and reproductive care), 3.8 (uni-
versal health coverage) and 3c (health workforce strengthening),
are required to achieve SDGs 3.1 (maternal survival), 3.2 (peri-
natal survival) and 3.4 (reduced impact of non-communicable
diseases (NCDs)). Medical solutions require greater clarity
around the classiﬁcation of the HDPs, increased frequency of
effective antenatal visits, mandatory responses to the HDPs when
encountered, prompt provision of life-saving interventions and
sustained surveillance for NCD risk for women with a history of
the HDPs.
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Introduction
The hypertensive disorders of pregnancy (HDPs), chronic (or pre-existing) hypertension, gestational
hypertension and, especially, pre-eclampsia, remain leading causes of maternal and perinatal
morbidity and mortality as well as identifying individuals at increased risk for premature cardiovas-
cular disease [1,2].
Diagnosis and classiﬁcation
Here we use the Canadian deﬁnitions and diagnostic criteria for, and classiﬁcation of, the
HDPs [3].
Blood pressure (BP) should be measured at each antenatal visit. Hypertension in pregnancy is
deﬁned by a systolic BP (sBP) 140 mmHg and/or diastolic BP (dBP) 90 mmHg [3]. Severe hyper-
tension is deﬁned as sBP160 mmHg (instead of 170 mmHg) as that level of sBP reﬂects stroke risk
[3e7]. Elevated BP should be conﬁrmed by repeat measurement, at least 15 min apart, being measured
three times, the ﬁrst value being disregarded and the average of the second and third taken as the BP
value for the visit [3].
We suggest screening with a urinary dipstick at each antenatal visit. Proteinuria diagnosis can
be performed on random samples (by a urinary dipstick or protein: creatinine ratio (PrCr)) or
timed urine collections (usually 24 h). Quantiﬁcation of urinary protein by 24-h urine collection is
often inaccurate [8] and has been replaced by spot urine samples outside pregnancy [9]. A dipstick
value of þþ proteinuria and PrCr of 30 g/mol represent signiﬁcant proteinuria of 0.3 g/d, the
current if ﬂawed gold standard (SOGC 32); a threshold up to 40 g/mol may be more appropriate in
multiple pregnancies (SOGC 33,34). Proteinuria should be quantiﬁed (by PrCr or 24-h urine
collection) if pre-eclampsia is suspected, as dipstick proteinuria <þþ has a signiﬁcant false
negative rate.
Chronic hypertension is deﬁned as hypertension that predates pregnancy, or appears before 20
weeks or persists more than 3 months postpartum. It can be complicated by superimposed pre-
eclampsia [3].
Gestational hypertension appears at 20 weeks and resolves by 3 months postpartum [3]. Asso-
ciated risks depend on the gestational age at presentation and progression to pre-eclampsia; gesta-
tional hypertension at <34 weeks is associated with a z35% risk of pre-eclampsia, which takes an
average of 5 weeks to develop [3].
Pre-eclampsia is the HDP associated with the greatest risks, particularly when it is severe or
present at <34 weeks [3,10,11]. The risk of small for gestational age (SGA) infants is primarily
among women who present at <34 weeks, with macrosomia more common with the term pre-
eclampsia [12]. Pre-eclampsia is most commonly deﬁned by new-onset proteinuria and poten-
tially other end-organ dysfunction. Table 1 outlines the end-organ dysfunction of pre-eclampsia:
‘adverse conditions’ and ‘severe complications’. ‘Adverse conditions’ consist of maternal symp-
toms, signs, abnormal laboratory results and abnormal foetal monitoring results that may herald
development of severe maternal or foetal complications (including stillbirth). The ‘adverse con-
ditions’ are those for which we wait and to which we respond (e.g., low oxygen saturation) to avoid
the severe complications that we wish to avoid entirely (e.g., pulmonary oedema). Remember that
a signiﬁcant minority of women will present with unheralded eclampsia [13]. That response
could be more intensive maternal or foetal monitoring, speciﬁc treatment or delivery. In the Ca-
nadian rubric, ‘severe complications’ of pre-eclampsia warrant delivery, irrespective of the
gestational age [3].
It must be recalled that delivery does not ‘cure’ pre-eclampsia; it only initiates the recovery from the
disease e and is the only intervention that will do so. Especially with early-onset pre-eclampsia, that
arising before 34 weeks of gestation, many women experience a transient deterioration in their clinical
state, with nadirs in platelet count and renal function and maximal liver enzyme abnormalities, before
their recovery. Frequently, this period of clinical vulnerability may last up to 72 h postpartum [1,2]. In
more developed countries, those women who die due to the consequences of pre-eclampsia almost
uniformly do so postnatally.
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The global impact of pregnancy hypertension
Maternal mortality
Complicating an estimated 3e10% of pregnancies [1,2], it has been estimated that the HDPs
cause 30,000 maternal deaths annually [14]. However, verbal autopsy data from Pakistan imply that
up to 40% of women who die from postpartum haemorrhage (PPH) complained of symptoms of pre-
eclampsia (e.g., headache, visual disturbances and abdominal pain) or had seizures prior to the
onset of their life-ending haemorrhage. It may be that a signiﬁcant proportion of these women had
pre-eclampsia that was complicated by disseminated intravascular coagulation, especially with the
occurrence of abruption, but were never noted to be hypertensive by the formal health system.
Such women would have bled sufﬁciently by the time of their presentation to mask their under-
lying hypertension; indeed, many will be hypotensive by the time they present for care. As PPH is
estimated to cause 40,000 maternal deaths [14], the actual number of maternal deaths caused by
the HDPs may be as high as 46,000 annually. Over 99% of these deaths occur in less-developed
countries [15].
As with most causes of maternal death, avoidable delays in triage, transport and treatment
contribute to a majority of HDP-related maternal deaths [16]. We believe that civil society has an
important, and hitherto under-mobilised, role to play in overcoming these delays. This is an important
theme to which we will return.
Table 1
Deﬁning the adverse features and severe complications of pre-eclampsia (modiﬁed from Magee et al Preg Htn).
Organ system
affected
Adverse conditions
(that increase the risk of severe complications)
Severe complications
(that warrant delivery)
Central nervous
system
 Headache and/or visual symptoms  Eclampsia
 PRES
 Cortical blindness or retinal detachment
 Glasgow coma scale <13
 Stroke, TIA, or RIND
Cardiorespiratory  Chest pain and/or dyspnoea
 Oxygen saturation <97%
 Uncontrolled severe hypertension (over a
period of 12 h despite use of three antihy-
pertensive agents)
 Oxygen saturation <90%, need for 50% ox-
ygen for >1 h, intubation (other than for
Caesarean section)
 Pulmonary oedema
 Positive inotropic support
 Myocardial ischaemia or infarction
Haematological  Elevated WBC count
 Elevated INR or aPTT
 Low platelet count
 Platelet count <50109/L
 Transfusion of any blood product
Renal  Elevated serum creatinine
 Elevated serum uric acid
 Acute kidney injury (creatinine >150 mM
with no prior renal disease)
 New indication for dialysis
Hepatic  Nausea or vomiting
 RUQ or epigastric pain
 Elevated serum AST, ALT, LDH, or bilirubin
 Low plasma albumin
 Hepatic dysfunction (INR >2 in absence of DIC
or warfarin)
 Hepatic haematoma or rupture
Foetoplacental  Non-reassuring FHR
 IUGR
 Oligohydramnios
 Absent or reversed end-diastolic ﬂow by
Doppler velocimetry
 Abruptionwith evidence ofmaternal or foetal
compromise
 Reverse ductus venosus A wave
 Stillbirth
AST e aspartate transaminase, ALT e alanine transaminase, aPTT e activated partial thromboplastin time, DIC e disseminated
intravascular coagulation, FHR e foetal heart rate, LDH e lactate dehydrogenase, INR e international normalised ratio,
PRES e posterior reversible leukoencephalopathy syndrome, RIND e reversible neurological deﬁcit 24e48 h, RUQ e right upper
quadrant, TIA e transient ischaemic attack 24 h, WBC e white blood cell.
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Maternal morbidity
Approximately 30% of all maternal near-miss events will be due to pregnancy hypertension [17,18],
with near-miss events complicating about 420/100,000 deliveries [19] and approximately 230,000
HDP-related near-miss events per year (assuming 185 million pregnancies per annum).
Stillbirth
Of the estimated 2.6 million stillbirths annually, approximately 16% occur in pregnancies compli-
cated by pregnancy hypertension [20]. Of particular importance to the global health community is the
fact that 11% of stillbirths are associated with pregnancies complicated by chronic hypertension, while
only 5% are associated with pre-eclampsia (presenting as either pre-eclampsia or eclampsia) [20]. The
global provision of effective antenatal surveillance could have a rapid impact on the association be-
tween chronic hypertension and stillbirth.
Neonatal mortality
It has been estimated that the HDPs precede 10% of early neonatal deaths (8/1000 live births) [21]
and a signiﬁcant proportion of late neonatal deaths (3/1000 live births) [22]. This would approximate
to about 1.5e2 million neonatal deaths annually.
Neonatal morbidity
Due to their association with iatrogenic prematurity, foetal growth restriction and foetal over-
growth, the HDPs are identiﬁable risk factors for newborn morbidity (e.g., respiratory distress and
neonatal hypoglycaemia) [23]. In addition, the rate of perinatal asphyxia, and resultant hypoxic-
ischaemic encephalopathy, is increased due to the links between imperfect placentation and accel-
erated placental ageing with the HDP [24,25]. Less recognised are the associations between maternal
pre-eclampsia and neonatal thrombocytopoenia and neutropoenia [23]. The rates of neonatal
morbidity will be inversely related to neonatal mortality rates, as survivability requires essential in-
terventions that range from Kangaroo mother care to access to neonatal intensive care. As a rule of
thumb, neonatal morbidities will occur 10e20 times more often than neonatal deaths.
Civil society-based solutions
There is increasing recognition of the importance and value of preconception care [26].Women and,
all too frequently, girls enter pregnancy within the continuum of their individual life cycle. In our
opinion, too often pregnancy has been focussed upon as a singular event that begins with either
conception or a positive pregnancy test. If the global community wishes to achieve the sustainable
development goal (SDG) 3.1, to reduce the global maternal mortality ratio to less than 70 per 100,000
live births by 2030 (http://www.un.org/sustainabledevelopment/health/), we need to intervene now to
alter young girls' and women's health and societal status.
How can such changes be achieved in the context of pregnancy hypertension? Here we elucidate
some possible solutions.
Community engagement and mobilisation
Prost and colleagues have assessed the effects of women's groups practising participatory learning
and action, compared with usual care, on birth outcomes in low-resource settings in Bangladesh, India,
Malawi and Nepal [27]. Exposure to women's groups was associated with a 37% reduction in maternal
mortality, a 23% reduction in neonatal mortality and a 9% trend towards a reduction in stillbirths. In a
meta-regression analysis, the proportion of pregnant women in groups was linearly associated with
reduction in both maternal and neonatal mortality, and if 30% of pregnant women participate in
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groups both maternal and neonatal mortality rates will fall (55% and 33%, respectively) in a cost-
effective manner.
Since that review, Colbourn and colleagues evaluated a rural participatory women's group com-
munity intervention (CI) and a quality improvement intervention at health centres (FI) via a two-by-
two factorial cluster randomised controlled trial (RCT) [28]. Following adjustment for clustering and
stratiﬁcation, the neonatal mortality rate was 22% lower in FI þ CI than control clusters and the
perinatal mortality rate was 16% lower in CI clusters. They were underpowered to assess maternal
mortality.
Through the Community-Level Interventions for Pre-eclampsia (CLIP) cluster RCTs in
Mozambique, Pakistan and India, we are testing the speciﬁc ability of HDP-oriented community
engagement to improve maternal and foetal outcomes (http://www.thelancet.com/protocol-
reviews/13PRT-9313). In the interim, and as pre-eclampsia and eclampsia can be detected in the
community, we suggest that the non-speciﬁc beneﬁts of community mobilisation are likely to
improve HDP-related health outcomes. Such mobilisation could most usefully include gaining prior
permissions to respond to maternal health emergencies for women without autonomy of decision-
making, transport planning and micro-insurance initiatives to cover the facility's out-of-pocket
expenses [29].
Food security for girls and pregnant women
For women to be of adequate stature and be in good health prior to, and during, pregnancy they
require food security from childhood e indeed, probably starting during foetal life and prior to their
own conception. To achieve SDG 3.1 by 2030, we must provide food security to today's girls. Short
stature (<164 cm) is associated with an approximate doubling of the risk for pre-eclampsia, especially
severe disease [30,31]. Short stature is observed signiﬁcantly in women who were undernourished as
girls [32]. Preferential feeding of male children and men, compared with girls and women, is prevalent
in many less developed countries [33].
Women from a food-insecure household are three times as likely to be severely obese compared
with women from food-secure households, after controlling for covariates: age, race, income, educa-
tion, marital status and the number of children [34].
Once pregnant, women from food-insecure households gain 1.9 kg more than women from food-
secure households [34]. In addition, Dean and colleagues have determined that maternal pre-
pregnancy weight is a signiﬁcant factor in the preconception period with being underweight
contributing to a 32% higher risk of preterm birth, while obesity more than doubles the risk for pre-
eclampsia and gestational diabetes [32]. Among nutrition-speciﬁc interventions, pre-conception folic
acid supplements prevent 69% of recurrent neural tube defects, and multiple micronutrient supple-
ments show promise of reducing the rates of congenital anomalies and risk of pre-eclampsia. While
vitamin C and E supplementation does not decrease the risk of developing pre-eclampsia, adequate
dietary intake of foods replete in antioxidants is associated with decreased rates of pre-eclampsia
[35e37].
Both hypertension and pre-eclampsia are more common in pregnant girls and women
who have insufﬁcient intake of elemental calcium, an effect that is reversed with calcium
replacement and supplementation [38,39]. Indeed, in women with a history of severe pre-
eclampsia, recent RCT data show that low-dose calcium replacement (500 mg/d to bring the
total intake to 1 g/d) in women during pregnancy lowers the mean dBP (2.6 mmHg) compared
with women taking a matched placebo (þ0.8 mmHg, mean difference 3.4 (95% CI 0.4 to 6.4),
p ¼ 0.025) [40].
Using cross-sectional data from India's third National Family Health Survey (NFHS-3, 2005e06),
data were obtained from 39,657 women aged 15e49 years, who had had a live birth in the ﬁve
years preceding the survey [41]. Women who had consumed either an adequately diversiﬁed diet
or folate and iron supplements were approximately 35% less likely to report symptoms of either
pre-eclampsia or eclampsia than women with inadequately diversiﬁed dietary intake. However,
we recognise that personal recall of pre-eclampsia symptoms or diagnoses is vulnerable to recall
bias.
P. von Dadelszen, L.A. Magee / Best Practice & Research Clinical Obstetrics and Gynaecology 36 (2016) 83e102 87
In terms of perinatal outcomes, Bhutta and colleagues estimate that maternal undernutrition
contributes to 800,000 neonatal deaths annually; stunting, wasting and micronutrient deﬁciencies are
estimated to underlie nearly 3$1 million child deaths annually [42]. They conclude that continued
investments in nutrition-speciﬁc interventions to avert maternal and child undernutrition and
micronutrient deﬁciencies through community engagement and delivery strategies, including
women's empowerment, agriculture, food systems, education, employment, social protection and
social safety nets, can greatly accelerate progress in countries with the highest burden of maternal and
child undernutrition and mortality.
Delayed marriage and delayed ﬁrst pregnancy
In many less developed country societies, marriage occurs early and is followed, in short order, by a
ﬁrst pregnancy. Both these events are modiﬁable through changes in civil societal expectations of girls
and women.
Obstetric outcomes have been determined for teenage pregnancies in Finland, a country with a low
teenage delivery rate and comprehensive high-quality antenatal care. In this privileged setting,
teenagers face increased risks of several obstetric complications, including a trebling of the risk for
developing eclampsia, while 13e15-year-olds have almost four times the odds for developing pre-
eclampsia compared with women aged 20e24 years old [43]. This adverse inﬂuence of teenage
pregnancy on maternal and perinatal outcomes is even stronger, compared with women in their
twenties, in less-developed countries.
Kumar and colleagues have observed that themajority of pregnant teenagers are primigravid (83.2%
vs. 41.4%) [44]. Gestational hypertension (11.4% vs. 2.2%), pre-eclampsia (4.3% vs. 0.6%) and eclampsia
(4.9% vs. 0.6%) are more common in teenagers than in women in their twenties. In terms of perinatal
risks, teenage mothers have pregnancies that are complicated more frequently by low birthweight
(50.4% vs. 32.3%), premature delivery (51.8% vs. 17.5%), stillbirth (1.9% vs. 0.3%), neonatal morbidities
(e.g., perinatal asphyxia (11.7% vs. 1.9%), jaundice (5.7% vs. 1.2%), respiratory distress (1.9% vs. 0.3%)) and
neonatal mortality (3.8% vs. 0.5%). Relating back to the discussion about food insecurity and its
contribution to obesity, the risks for a woman to develop either pre-eclampsia or eclampsia increase
signiﬁcantly with increasing bodymass index (BMI) and decreasing age. Extremely obese teenagers are
almost four times as likely to develop pre-eclampsia and eclampsia when compared with non-obese
women aged 20e24 years of age [45].
There is convincing evidence that prior and prolonged exposure to paternal antigens may reduce
the likelihood of pre-eclampsia [46]. Sexual and reproductive practices that minimise maternal
exposure to paternal seminal ﬂuid prior to pregnancy have been associated with an increased risk of
pre-eclampsia. For example, women above the highest 10th percentile of vaginal exposure to
paternal semen have a 70% reduced odds of developing pre-eclampsia compared with women below
the lowest 25th exposure percentile [46]; these data are consistent with our growing understanding
of the role of innate immunity in modulating trophoblast invasion during the ﬁrst and second tri-
mesters [1,2,47].
Birth spacing
From the literature on primarily more developed countries, it is well recognised that either a too
short (<2 years) or too long (>10 years) birth interval increases a woman's risk for developing pre-
eclampsia, especially recurrent disease [3]. In a less-developed country setting, De Jonge and col-
leagues analysed 5571 second- or higher-order deliveries in rural Bangladesh [48]. Younger women,
women who deferred their fertility and those who achieved higher order parities were less likely to
experience short birth intervals. Women who were socio-economically disadvantaged were more
likely to experience a short birth interval, and a previous adverse outcome appeared to motivate
women to delay a future pregnancy. Very short birth intervals of less than 21 months more than
double the odds of either a stillbirth or newborn death. Therefore, giving women a reproductive
choice is an important tool in reducing the HDP-related burden of adverse maternal and perinatal
events.
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Facilities
Other important elements of societal responsibility to women whose pregnancies are complicated
by the HDP are facility availability and enhancement. While community-based screening will identify
women with hypertension, accessible and effective health facilities, staffed continuously by respectful
and skilled health practitioners providing evidence-based care, are required to provide the essential
life-saving interventions discussed in detail below. Commodity security for these diagnostic tools,
medicines and emergency obstetric care provision is the responsibility of all levels of health systems,
from local stock-taking through to regional and national governments [49].
Beyond the commodities required to modify disease-speciﬁc risks of stroke and eclampsia, facilities
need to fulﬁl water, sanitation and hygiene (WASH) standards to provide safe care [50], especially as
the only deﬁnitive method to initiate recovery from pre-eclampsia is delivery of the placenta [3]. This
requires either labour induction or Caesarean delivery, the safety of both of which are WASH depen-
dent. Campbell and colleagues have provided a carefully framed conceptual framework, linking WASH
to improved maternal and reproductive health outcomes [51].
An example of how to mobilise funds for facility availability and enhancement is the experience of
the Local Authority Transfer Fund in Kenya. This fund returns 5% of income tax to communities in a
proportional manner, which has improved both accountability and community autonomy. A conse-
quence has been an improvement in government income tax-based revenues, as communities see the
return on their taxation being used to build such things as schools, health facilities and transport
infrastructure [52]. Improvements across these infrastructures will lead to improved maternal and
perinatal health outcomes.
Medical solutions
Health human resources
To support women during and after pregnancy, as well as their newborns, there needs to be an
adequate health human resources infrastructure available to womenwherever they live. Of the leading
causes of maternal and perinatal mortality, the HDPs are those most amenable to a community-
oriented approach as there is usually a lead time between the onset of symptoms and signs of pre-
eclampsia and the evolution to life-threatening and life-ending complications.
Within communities, in CLIP, we are taking the approach of task-shifting the screening, initial
diagnosis and initiation of lifesaving therapies to mobile health (mHealth)-supported community
healthcare providers in women's communities (http://www.thelancet.com/protocol-reviews/13PRT-
9313). These workers are agentes polivalentes elementares, lady health workers, and both accredi-
ted social health activists and auxiliary nurse midwives in Mozambique, Pakistan and India, respec-
tively. An element of the mHealth-directed response to the detection of hypertension is either urgent
(within 4 h) or non-urgent (within 24 h) transfer to referral facilities that provide comprehensive
emergency obstetric care; the mHealth app, pre-eclampsia integrated estimate of risk (PIERS) on the
Move (POM), has speciﬁc thresholds to guide women to seek urgent, rather than non-urgent, care
(refs). However, it is important to recognise the increasing burden being placed on such workers
through task-shifting in many countries e if this cadre of workers is to remain effective and accept
more tasks, it requires an expansion in numbers and adequate support through pre-deployment
training and ongoing professional development and supervision.
Once women reach health posts, primary health centres and inpatient facilities, they require access
to trained and effective nurses, midwives, physician assistants and doctors. For maternity care, the
global call is for strengthening and expansion of the midwifery workforce [53]. It is incumbent on
whoever provides maternal and perinatal healthcare to do so respectfully, utilising the best evidence-
based approach that local resources permit [54,55]. Improving work environments will increase the
likelihood of women receiving respectful care [56].
In all settings and at all levels, maternity care providers are obliged to undertake continuous pro-
fessional development (CPD) tailored to their educational and skill levels e and national professional
societies and ministries are obliged to provide CPD and the time to attend CPD courses.
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Screening for HDP risk
Approximately 1% of women live with chronic hypertension when they conceive, but at a global
level, most of them are unaware of that. Therefore, routine antenatal BP measurement will identify
hypertensive women, of whom many will be shown to have chronic hypertension as they remain
hypertensive beyond 6 weeks postpartum.
The strongest clinical markers of pre-eclampsia risk identiﬁable at antenatal booking are recom-
mended for screening for pre-eclampsia in the community [3]. Of the nine clinical predictors of pre-
eclampsia among nulliparous women carrying singleton pregnancies, one is protective (miscarriage
at10 weeks with the same partner) and eight increase risks (younger maternal age, higher BP, higher
BMI, family history of pre-eclampsia or coronary heart disease, woman with lower birthweight
themselves, vaginal bleeding during early pregnancy and short duration of sexual relationship). Half of
the women destined to develop pre-eclampsia would be detected using the model [3]. First-trimester
uterine artery Doppler shows promise but needs further ‘real-life’ evaluation [3].
Second- and third-trimester markers of pre-eclampsia risk include measures of placental perfusion,
vascular resistance and morphology; maternal cardiac output and systemic vascular resistance; foe-
toplacental unit endocrinology; maternal renal function; maternal endothelial function and endo-
thelialeplatelet interaction, oxidative stress, circulating angiogenic factors and glycosylated
ﬁbronectin [1e3,47,57]. Other than direct clinical measurements of BP and proteinuria, most of these
tests are limited to well-resourced settings. As no single test predicts pre-eclampsia with sufﬁcient
accuracy to be clinically useful [1e3,58], interest has grown in researching multivariable models that
include clinical and laboratory predictors available at booking and thereafter [1e3,59]. We await the
results of deﬁnitive studies.
Prevention of pre-eclampsia
Calcium replacement and supplementation
Lassi and colleagues have systematically reviewed calcium supplementation (1e2 g/d) for the
prevention of pre-eclampsia and determined that calcium supplementation signiﬁcantly reduces the
risk of pre-eclampsia by 55% and by 64% in women with a low dietary intake of calcium [60]. In
addition, calcium supplements have a signiﬁcant protective effect on maternal mortality and serious
morbidity and preterm birth, with trends to lowering risks for low birthweight and stillbirth.
Since this review, Hofmeyr and colleagues have reviewed the RCTs of calcium replacement (<1 g/d)
rather than supplementation (1e2 g/d) [39]. Pre-eclampsiawas reduced consistently by an average 62%
with replacement, with orwithout co-supplements. The overall results were consistentwith the single-
quality trial of calcium replacement alone. Of note, one small trial of 60 women observed a statistical
trend of >90% reduction in the miscarriage risk for women taking calcium replacement combined with
antioxidants commencing at 8e12 weeks. These limited data are consistent with calcium replacement
reducing the risk of pre-eclampsia. Currently, Professor Hofmeyr is conducting the calcium and pre-
eclampsia trial, assessing the ability of pre-pregnancy calcium replacement to prevent recurrent pre-
eclampsia (http://www.thelancet.com/protocol-reviews/11PRT-4028). Establishing a lower dose
would have signiﬁcant implications for the current guidelines and their global implementation.
Antiplatelet agents (low-dose aspirin) for prevention of pre-eclampsia
Results of the Lassi review show that antiplatelet agents are associatedwith a consistent reduction in
pre-eclampsia (17% reduction)and preterm births <34 weeks (8% reduction) and a 14% reduction for all
types of perinatal deaths (foetal, neonatal, infant) [60]. We recommend that antiplatelet agents should
be given to pregnantwomenat a high risk of pre-eclampsia or thosewith gestational hypertension, since
they lead to reduction of vast adverse outcomes of pregnancy for both the mother and the newborn.
Provision of antenatal care
While access to both antihypertensives and magnesium sulphate clearly matters, in our opinion the
greatest health system priority to improve maternal and perinatal outcomes is the provision of
P. von Dadelszen, L.A. Magee / Best Practice & Research Clinical Obstetrics and Gynaecology 36 (2016) 83e10290
effective maternity care. The World Health Organisation four-visit model is associated with increased
risks of perinatal loss [61], and this probably relates to the gap in antenatal surveillance between 36
weeks and delivery. Most HDPs present or deteriorate either near or at term. The accelerating pattern
of antenatal visits (four-weekly visits until 28 weeks, fortnightly to 36 weeks and weekly thereafter)
was designed in Edinburgh largely for the identiﬁcation of pre-eclampsia to afford the opportunity for
timely delivery [62]. Since the ﬁrst triennial report of the UK Conﬁdential Enquiries into Maternal
Deaths (1952e54), pre-eclampsia- and eclampsia-related deaths have fallen by approximately 90%
[63]. Over 90% of that fall was achieved prior to the introduction of either effective antihypertensives
for the management of pregnancy hypertension [64] or the use in the UK of magnesium sulphate for
eclampsia prevention and treatment following the Collaborative Eclampsia and Magpie Trials,
respectively [65,66]. Once a diagnosis has been made, then an adequate health system can respond
through the provision of inpatient care, ongoing surveillance, BP control, seizure prophylaxis and timed
delivery. Similar data exist for Sri Lanka following the introduction of comprehensive maternity care,
including vital registration, registration of midwives, prenatal coverage (health centre- and home-
based) and facility strengthening [67]. Therefore, personalised risk assessment through antenatal
care is an effective tool for reducing adverse pregnancy outcomes, especially when included in a
package of health-service enhancements.
Detection of the HDP
Blood pressure
BP measurement remains a cornerstone of the screening for, and diagnosis of, pre-eclampsia
[3,63,68]. An important advance in the move toward offering every pregnant woman accurate BP
measurement and detection of pregnancy hypertension has been the development of the semi-
automated Microlife BP 3AS1-2 sphygmomanometer®, which has been validated in women with the
hypertension of pre-eclampsia [69]. This device avoids the errors intrinsic in manual BP measurement
in pregnancy (especially terminal digit preference [70], can be used by minimally trained community-
level healthcare providers and costs less than $25 USD per unit.
Urinary protein measurement
The obstetric gold standard of 24-h urine collection is frequently inaccurate and not a precise
measure of either proteinuria or creatinine clearance [8]. Additionally, a recent systematic reviewof the
spot PrCr and albumin: creatinine (ACR) ratios as diagnostic tests for signiﬁcant proteinuria (compared
with 24-h collection) in hypertensive pregnant women determined that the spot PrCr ratio (cut-off
point, 30 g/mol) is a reasonable “rule-out” test for detecting signiﬁcant proteinuria of 0.3 g/day or more
in hypertensive pregnancy [71]. Practitioners using either 24-h collections and/or the PrCr ratio in
pregnancy must be particularly aware of the interaction between the protein estimation method and
urinary concentration, as the pyrocatechol violet-dye method is vulnerable to overestimating urinary
protein in dilute urine [63]. Information related to the use of the ACR in pregnant women remains
insufﬁcient to guide practice [63]. In pregnancy, urine is often dilute, and we found that almost 25% of
ACR results are clinically uninformative [72].
Within the PIERS cohort, dipstick proteinuria performs as well (or poorly) as other methods of
assessing proteinuria for prediction of adverse outcomes [73]. Our ﬁndings support the view that
once signiﬁcant proteinuria has been identiﬁed (by dipstick [þþ], PrCr ratio or 24-h collection),
further proteinuria assessment should not be used to guide clinical decision-making related to either
short- or long-term maternal prognosis. Rather, the serum creatinine value should be used to
monitor renal function and risk in women with pre-eclampsia [11]. In settings without laboratory
support, the heaviness of dipstick proteinuria is predictive of adverse perinatal, but not maternal
outcomes [10].
Time-of-disease maternal risk assessment
Not all women with pregnancy hypertension are destined to either die or suffer permanent
sequelae. Therefore, our PIERS initiative has been an investigating tool to provide personalised risk
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assessment and medicine to womenwho have a diagnosis of a HDP. In the studies summarised below,
the outcome of interest was maternal mortality or other serious complications of pre-eclampsia [11].
We have assessed the performance of maternal symptoms, proteinuria, oxygen saturation by pulse
oximetry (SpO2), uric acid, platelet counts and liver tests individually to identify those hypertensive
pregnant women who are more likely to suffer severe complications [73e78]. Of these, only SpO2
showed any capacity as a test that can be used in isolation, including predicting non-cardiorespiratory
adverse maternal outcomes (area under the receiver-operator characteristic (AUC ROC) >0.7) [77].
Therefore, we deemed that multivariable models were required.
Resource-constrained settings
We developed and validated the demographics-, symptom- and sign-based miniPIERS risk pre-
diction model to provide a simple, evidence-based tool to identify pregnant women in resource-
constrained settings at increased risk of death or major hypertensive-related complications [10].
Developed and validated on 2081womenwith any HDP admitted to a participating centre in Brazil, Fiji,
Pakistan, South Africa and Uganda, the ﬁnal miniPIERS model included parity (nulliparous vs.
multiparous), gestational age on admission, headache/visual disturbances, chest pain/dyspnoea,
vaginal bleeding with abdominal pain, sBP and dipstick proteinuria. The miniPIERS model was well
calibrated and had an area under the receiver operating characteristic curve (AUC ROC) of 0.77. External
validation AUC ROC using the fullPIERS cohort (below) was 0.71. A predicted probability25% to deﬁne
a positive test classiﬁed women with 85.5% accuracy. Our conclusion is that miniPIERS can be used to
identify women who would beneﬁt most from interventions such as magnesium sulphate, antihy-
pertensives or transportation to a higher level of care.
To strengthen miniPIERS, we used South African and Pakistani data to recalibrate and extend
miniPIERS to include SpO2 [79]. Women with SpO2 < 93% had a 30-fold increase in risk of adverse
maternal outcome compared with those with SpO2 > 97%. After recalibration and extension, the
miniPIERS model including SpO2 (vs. not including SpO2) had improved sensitivity (32.8% vs. 49.6%) at
the cost of minimally decreased speciﬁcity (91.5% vs. 96.2%).
In the CLIP trials, we are testing the performance of miniPIERS, and other thresholds that mandate
an urgent response, using country-speciﬁc versions of the POM app [80,81]. The POM app provides
culturally sensitive, easy-to-use guidance for community healthcare providers. In rural Sindh, for
example, a lady health worker is guided through antenatal screening, BP measurement and, if the
pregnant woman is hypertensive, a range of responses that can include lady health worker-
administered magnesium sulphate (for women at high risk) and, if the woman is severely hyperten-
sive, oral methyldopa, prior to urgent referral for deﬁnitive facility-based care. If thewoman is assessed
as having less risk, then she is advised to seek facility-based care within 24 h.
Well-resourced settings
We developed and internally validated the fullPIERS model with the aim of identifying the risk of
fatal or life-threatening complications inwomenwith pre-eclampsia within 48 h of hospital admission
to tertiary obstetric centres in Australia, Canada, New Zealand and the UK [11]. Independent predictors
of adverse maternal outcome included in fullPIERS are gestational age, chest pain or dyspnoea, SpO2,
platelet count and serum creatinine and aspartate transaminase concentrations. FullPIERS predicted
adverse maternal outcomes within 48 h of study eligibility (AUC ROC 0$88) and performed well (AUC
ROC >0$7) up to 7 days after eligibility. In addition, we reassessed the performance of fullPIERS using
predictor variables obtained within 6 and 24 h of admission and found that the stratiﬁcation capacity,
calibration ability and classiﬁcation accuracy of the model remained high [82].
Akkermans and colleagues performed an external validation of fullPIERS using prospectively
collected data from two tertiary care obstetric centres that participated in the Pre-eclampsia Trial
Amsterdam (PETRA) [83] and observed that fullPIERS predicted adverse maternal outcomes within
48 h (AUC ROC 0.97) and up to 7 d after inclusion (AUC ROC 0.80). More recently, in prospective external
validation cohort in India, women with a >30% predicted probability were 17.5 times more likely to
experience adverse maternal outcome, implying that fullPIERS has particular strength as a “rule-in”
test [84]. Further external and temporal validation of fullPIERS is underway, and a fullPIERS mHealth
app is being developed.
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Time-of-disease foetal risk assessment
Resource-constrained settings
The primary method for detection of the at-risk foetus has been maternal awareness of decreased
foetal movement. Winje and colleagues have performed a systematic review of randomised and NRSs
assessing the effects of interventions to enhance maternal awareness of decreased foetal movement
[85]. Results were not pooled due to substantial heterogeneity between studies. Three RCTs and ﬁve
NRSs assessed the effects of interventions on stillbirth and perinatal death. RCT data are inconclusive
for the prevention of stillbirth. All NRSs favoured intervention over standard care; three studies re-
ported signiﬁcant while two reported non-signiﬁcant reductions in stillbirth or perinatal deaths.
Therefore, on balance, the evidence supports awareness of foetal movement being beneﬁcial.
In addition to foetal movements, within the PIERS initiative, we have developed and internally
validated a prognostic model for perinatal death that could guide community-based antenatal care of
women with a HDP in low-resourced settings as part of an mhealth application [86]. Of the 1688
women admitted 32þ0 weeks' gestation with a HDP from the ﬁve low-resourced countries in the
miniPIERS cohort, 110 (6.5%) suffered a perinatal death. A logistic regression-derived model to predict
perinatal death included maternal age, a count of symptoms (0, 1 or 2) and dipstick proteinuria. The
AUC ROC is 0.75. The model, which excluded foetal movements due to unavailability of that variable,
correctly identiﬁed 42/110 (38.2%) additional cases as high risk (probability >15%) of perinatal death
compared with the use of only gestational age.
Well-resourced settings
Most experts suggest that the use of non-stress tests/cardiotocography (NST/CTG) be restricted to
high-risk groups only, including women with pre-eclampsia [12]. However, evidence is lacking to
either support this practice or guide the practitioner on the frequency of testing. Most authorities
suggest that women with mild pre-eclampsia undergo weekly NST/CTG, whereas those with severe
early-onset pre-eclampsia (in particular, in the presence of foetal growth restriction or oligohy-
dramnios) be followed at least twice weekly [12]. The authors of a recent Cochrane review concluded
that ‘there is almost no evidence to date to indicate an optimal antenatal surveillance method for
infants identiﬁed with impaired growth’ [87], highlighting the urgent need for research in this area.
In the context of both pre-eclampsia and intrauterine growth restriction (IUGR), the use of the
biophysical proﬁle tends to falsely reassure, leading to an excess of adverse perinatal events [88e90].
Doppler velocimetry can be used in the assessment of foetuses from high-risk pregnancies,
including IUGR and pre-eclampsia (particularly early-onset disease). Umbilical-artery Doppler
assessment in high-risk pregnancies is associatedwith a 29% reduction in perinatal mortality, as well as
10% fewer inductions of labour and Caesarean deliveries [12]. The combination of abnormal middle
cerebral artery peak systolic velocity and reversed ﬂow in the ductus venosus increases the risk of
perinatal mortality by 10-fold [12].
At this time, the available evidence suggests that, in cases of pre-eclampsia associated with IUGR,
integrating Doppler, NST/CTG and ﬂuid assessment may help further deﬁne the risk of perinatal death
and assist in determining the optimal timing of delivery [12]. However, as there is no outcome pre-
diction model that integrates and weights the independent value of each of these parameters, we
believe that research to develop and validate a fullPIERS-like model for high-risk foetuses is required.
Treatments
Non-severe hypertension
BP-pressure targets for women with non-severe hypertension during pregnancy have been
much debated. The Control of Hypertension in Pregnancy Study (CHIPS) trial was an open, inter-
national, multicentre RCT [91]. CHIPS recruited 987 women at 14þ0e33þ6 weeks, who had non-
proteinuric chronic (74.6%) or gestational (25.4%) hypertension, an ofﬁce dBP of 90e105 mmHg
(or 85e105 mmHg if taking antihypertensive medications) and a live foetus, to receive either less-
tight (target dBP 100 mmHg) or tight (target dBP 85 mmHg) control. The rates of pregnancy loss or
high-level neonatal care >48 h during the ﬁrst 28 postnatal days did not differ between the less-
P. von Dadelszen, L.A. Magee / Best Practice & Research Clinical Obstetrics and Gynaecology 36 (2016) 83e102 93
tight and tight control groups (31.4% and 30.7%, respectively) and neither did maternal complica-
tions (3.7% and 2.0%, respectively), despite a mean dBP that was higher in the less-tight control
group by 4.6 mm Hg. Severe hypertension (160/110 mm Hg), a threshold for stroke risk, developed
in 40.6% of the women in the less-tight control group and in 27.5% of the women in the tight-
control group e a difference that is highly signiﬁcant, both statistically and, for women, clinically.
In CHIPS, methyldopa and labetalol were used commonly both at randomisation (24.6% and 24.6%,
respectively) and post randomisation (22.8% and 44.1%, respectively). Following adjusted analyses,
methyldopa (vs. labetalol) at randomisation was associated with fewer babies with a birthweight
<10th centile. Methyldopa (vs. labetalol) post randomisationwas associated with fewer CHIPS primary
outcomes, birthweight <10th centile, severe hypertension, pre-eclampsia and delivery before both 34
and 37 weeks [92].
While CHIPS was limited to non-proteinuric women with hypertension, we believe that the results
are relevant to women with pre-eclampsia. On balance, we believe that tight control is the preferred
response for all types of pregnancy hypertension, especially in resource-constrained settings where
access to follow up and surveillance is more limited. This approach is not deleterious to the foetus, adds
maternal safety by keeping women away from severe hypertension and is consistent with approaches
outside pregnancy. Methyldopa appears to be the preferable agent due to its effects, presence of
essential medicines lists [93] and, for under-resourced settings, cost; the other options are listed in
Table 2. Note that angiotensin-converting enzyme inhibitors (e.g., captopril) and angiotensin-2 re-
ceptor blockers (e.g., lisinopril) should not be used due to the increased risk of stillbirth with their use
[3,64].
Severe hypertension
A sBP 160 mmHg and/or dBP 110 mmHg requires a response, with immediate targets being to
lower BP to under those thresholds within hours [1,3,64,68]. Severe systolic hypertension is an inde-
pendent risk factor for stroke in pregnancy [4e7]. The UK ‘Conﬁdential Enquiries into Maternal Deaths’
has identiﬁed failure to recognise the severity of and to treat the severe (particularly systolic) hyper-
tension of pre-eclampsia as the single most serious failing in the clinical care of those womenwho died
from strokes [6,7].
Such acute elevations in BPmay reﬂect either the development or progression of pre-eclampsia and
should precipitate detailed clinical, laboratory and ultrasound assessment of the pregnancy.
Our antihypertensive of choice for severe pregnancy hypertension is oral nifedipine (either capsule
or intermediate-acting tablet) because it has a more reliable effect than both labetalol and hydralazine
and less frequent occurrence of drug-induced hypotension [63]. Nifedipine is safe to use with con-
current magnesium sulphate [63]. Our preference is for oral agents in non-obtunded women as their
use can be initiated by nurses/midwives rather than the common requirement for the doctor's pres-
ence for an intravenous agent; the presence of a doctor can be delayed because of concurrent activities
such as Caesarean deliveries.
Within the context of the PRE-EMPT initiative, Gynuity Health Projects are conducting a RCT with a
head-to-head comparison of three oral antihypertensives for severe pregnancy hypertension, nifedi-
pine, labetalol and methyldopa (http://pre-empt.cfri.ca/treatment/treatmentgynuity-trial). The results
of this trial will be pertinent to all caregivers.
As a rule of thumb, our approach is to reserve nifedipine for use in women with severe pregnancy
hypertension and to use either labetalol and/or methyldopa for longer term medication to achieve
synergism of effect and to use beta-blockade to avoid the acute cardiovascular risks associated with
nifedipine capsules. In addition, if a woman experiences an acute elevation in her BP on, say, labetalol,
it seems logical to us not to use more of that agent for acute BP control. Effective antihypertensives are
available in all settings to manage severe pregnancy hypertension [63,64] (Table 2).
Prevention and treatment of seizures
Magnesium sulphate is the ﬁrst-line treatment of eclampsia and its prevention, especially in
women with severe disease [3,68]. We reviewed current regimens in less developed countries for
magnesium sulphate [94]. The commonly used regimens are 14 g Pritchard loading dose (4 g iv þ 10 g
im), full Pritchard regimen (same loading dose þ 5 g/4 h im maintenance), an im loading dose only
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Table 2
Commonly used agents for severe and non-severe pregnancy hypertension (modiﬁed from PvD CHR).
Indication/Agent Dosage Onset Peak Duration Comments
Severe hypertension
Hydralazine Start with 5 mg iv; repeat 5e10 mg iv every
3 min, or 0.5e10 mg/h iv, to a maximum of
20 mg iv (or 30 mg im)
5 min 30 min 2e4 h May increase the risk of maternal hypotension.
Appears less effective than nifedipine but more
effective than labetalol.
Labetalol iv Start with 20 mg iv; repeat 20e80 mg iv every
30 min, or 1e2 mg/min (then switch to oral
(max 300 mg))
5 min 30 min 4 h Best avoided in women with asthma or heart
failure.
Neonatology should be informed if the woman
is in labour, as parenteral labetalol may cause
neonatal bradycardia.
Labetalol po 200 mg loading dose; repeat further 200 mg
doses every 45 min (then switch to regular oral
(max 1200 mg/d))
20 mine2 h 1e4 h 8e12 h
(dose-dependent)
Nicardipine iv Initial infusion rate 2.5e5 mg/h, increasing by
2.5 mg/h every 5 min (max 15mg/h)
5 min 20 min 4e6 h Currently not recommended as a ﬁrst-line agent
by any national or international guideline
committee
Nifedipine capsule 5e10 mg capsule to be swallowed or bitten
then swallowed every 30 min
5e10 min 30 min z6 h Be aware of the distinction between short-
acting nifedipine capsules, the intermediate-
acting tablets and the slow-release tablets.
Avoid nifedipine capsules in women with
known coronary artery disease, severe aortic
stenosis and pre-existing diabetes of 15 y
duration due to risks of acute coronary
syndromes.
Nifedipine
intermediate-acting/PA
10 mg tablet; repeat 10 mg doses every 45 min
(then switch to regular oral medication) (max
120 mg/d)
30 min 4 h 12 h
Non-severe hypertension
Methyldopa 250e500 mg po bid-qid (max 2 g/d) 40 min 3e6 h 12e24 h There is no evidence to support a loading dose
of methyldopa. CHIPS data suggest that
methyldopa is preferable to labetalol. There are
reassuring neurodevelopmental data for
methyldopa.
Labetalol 100e400 mg po bid-tid (max 1200 mg/d) 20 mine2 h 1e4h 8e12 h
(dose-dependent)
Best avoided in women with asthma or heart
failure.
Some experts recommend a starting dose of
200 mg po bid.
Nifedipine
intermediate-acting/PA
10-40 mg tablet po bid-tid (max 120 mg/d) 30 min 4 h 12 h Be aware of the distinction between short-
acting nifedipine capsules, the intermediate-
acting tablets and the slow-release tabletsNifedipine XL preparation 20e60 mg po OD (max 120 mg/d)) 60 min 6 h 24 h
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regimen (10 g im; without the 4 g iv), the Zuspan regimen (4 g iv loading dose þ 1 g/h iv) and the Sibai
regimen (4 g iv loading dose þ 2 g/h). Most regimens use additional 2 g iv/im if seizures occur after
initiation of therapy. The Zuspan regimen then increases the maintenance dose to 2 g/h.
In terms of task-shifting, a single RCT of community administration of a magnesium sulphate
loading dose before referral to a facility versus limiting treatment to facilities reduced the occurrence of
recurrent eclampsia by 78%. Due to concerns related to maternal safety, cost and resource availability,
there has been an interest in alternative regimens for magnesium sulphate administration, particularly
in less-developed countries; however, we do not support moving to abbreviated or lower dose courses
until adequately powered and well-designed RCTs have been published [63,94]. In addition, clarifying
exactly who among women with non-severe pre-eclampsia requires magnesium sulphate, how much
women should receive and for how long remains a research priority.
We believe that the continued use of benzodiazepines, phenytoin or lytic cocktail to be dangerous
and requiring robust and sustained efforts by national societies and health administrators to be halted.
Foetal neuroprotection
In addition to its use for eclampsia prophylaxis and treatment, in women with pre-existing or
gestational hypertension, magnesium sulphate should be considered as a cost-effective therapy to
decrease the risk of cerebral palsy (and ‘death or cerebral palsy’) in the setting of ‘imminent preterm
birth’ (within the next 24 h) up to 33þ6 weeks [95,96]. We advocate using the same regimen for foetal
neuroprotection as clinicians use for eclampsia prevention and treatment. This will reduce dosing
errors and strengthen conﬁdence in magnesium sulphate use.
Magnesium sulphate for foetal neuroprotection should not be used concurrently with tocolysis. Its
use should be limited to when the clinician is certain of early preterm birth e the loading dose alone
appears to be effective.
Antenatal corticosteroids
When administered at 34þ6 weeks, antenatal corticosteroids accelerate foetal pulmonary matu-
rity and decrease neonatal mortality and morbidity, including women with HDPs [3]. RCTs that
administered steroids at 33þ0e34þ6 weeks resulted in reduced neonatal RDS [3], a subject of ongoing
trials. The beneﬁcial effects of steroids can be observed when the ﬁrst dose is administered as late as
within 4 h before birth. As long as dating is secure, there is no evidence of short- or long-termmaternal
or foetal adverse effects of a single course of antenatal corticosteroids. Inaccurate dating and the use of
corticosteroids close to term may cause harm [97].
If expectantly managed, women with pre-eclampsia remote from term (usually <34þ0 weeks)
will deliver within two weeks of corticosteroid administration, but the duration of pregnancy
prolongation varies from hours to weeks. All eligible women with pre-eclampsia should receive
antenatal corticosteroids. If women with pre-eclampsia remain pregnant seven or more days after
their initial course, then a single, and only a single, rescue course of corticosteroids appears to be
warranted [98].
Fluids
Routine preloadingwith a ﬁxed volume of crystalloid (i.e., 500e1000mL) will not prevent BP falls in
normal women prior to Caesarean delivery [3]; no speciﬁc studies exist for HDPs. Preloading may
increase the risk of life-threatening pulmonary oedema [3]. Hypotension should be treated with va-
sopressors as an infusion or small boluses [3].
Oliguria (<15 mL/h) is common in pre-eclampsia, particularly postpartum. In the absence of pre-
existing renal disease or a rising creatinine, oliguria should be tolerated over hours, to avoid
volume-dependent pulmonary oedema [3]. Fluid balance should be closely monitored and frusemide
limited to pulmonary oedema treatment [3].
When to deliver
In response to the new Canadian deﬁnition of severe pre-eclampsia, any woman with severe pre-
eclampsia should deliver [3,63]. The manner of that delivery will be determined by the woman's
gestational age and other obstetric factors.
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At term. Women at term (36þ0 weeks) with either pre-eclampsia or non-proteinuric gestational
hypertension are best managed by a policy of induction of labour [3,63]. Among women randomised
37þ0 weeks, for every seven labour inductions, there was one fewer Caesarean delivery. Womenwith
chronic hypertension appear to beneﬁt most from induction at 38þ0e39þ6 weeks [99].
Near term. However, a policy of induction near term (34þ0e36þ6 weeks) is associated with no
measurable beneﬁt for mothers, but with threefold greater risks of newborn respiratory distress [3].
Remote from term. Remote from term, RCT, case-control and cohort data support a policy of expectant
(vs. interventionist) care [63]. Generally, about half of the women will remain undelivered 48 h after
presentation (timeframe for antenatal corticosteroid administration and effect) and be eligible for
expectant management. In RCTs, the in utero time gained from eligibility to delivery is about 14 days,
whereas in non-RCT studies, the time gained is generally 7e10 days.
Expectantmanagement should only be attempted in institutions experienced in themanagement of
pre-eclampsia. Failure to provide obsessive surveillance during expectant management is a life-
threatening gap in care [63]. For women who present before 24 weeks' gestation (or local limits of
viability), expectant management is unlikely to offer any perinatal advantages while maternal risks
persist and rise [63]. For such women with pre-viability pre-eclampsia, the offer of pregnancy
termination for maternal indications should be made. This remains an option denied to women in
many societies where full reproductive choice is withheld.
When a decision is made to pursue delivery at term gestational ages, vaginal delivery is a viable
option if the maternal and foetal conditions allow it, although Caesarean delivery rates are signiﬁcant
(14e19%) [100]. At lower gestational ages, rates of successful vaginal delivery are better than might be
anticipated: 69% at 32þ0e33þ6 weeks and 48% at 28þ0e31þ6 weeks. However, vaginal delivery is rarely
achieved at less than 28 weeks (7%) [100].
Long-term health and non-communicable diseases (NCDs): addressing the SDGs between generations
The mothers
Women who develop a HDP, deliver preterm and have a baby with the lowest quintile of birth-
weight acquire similar risk for premature cardiovascular disease as women who smoke [101].
Any weight gain between pregnancies predicts pre-eclampsia and other pregnancy complications
[3]. Observational data suggest that inwomenwho aremorbidly obese, bariatric surgery lowers rates of
subsequent HDP [3]. Women with pre-existing hypertension should receive recommended cardio-
vascular risk factor screening and treatment [3].
As pregnancy is a biological ‘stress test’ of sorts, women with a prior HDP (particularly associated
with preterm delivery or adverse perinatal outcome) should be informed of their increased future
health risks, including hypertension, cardiovascular and cerebrovascular morbidity and mortality,
subsequent renal disease, thromboembolism, hypothyroidism and type 2 diabetes mellitus [3].
Barriers to compliance with a healthy diet and lifestyle include poor postpartum physical and psy-
chological recovery and lack of postpartum medical and psychological support from healthcare
providers [3]. These barriers need to be addressed in a way that is both culturally responsive and
effective.
The offspring
The increasingly robust evidence for developmental origins for health and disease is of particular
importance as the world moves to embrace the SGDs. Approximately 20% of a person's risk for pre-
mature cardiovascular disease is determined by birth. Girls who are born small due to the modiﬁable
sociocultural factors discussed above are more likely to have pregnancies complicated by HDPs as well
as premature cardiovascular disease. Interventions across the spectrum are likely to create a virtuous
cycle that will accelerate progress towards the NCD elements of the SDGs.
Pre-eclampsia is a robust predictor of cardiovascular and reproductive health in the offspring of
those pregnancies [3].
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D Effects of maternal hypertension and its therapies on child neurobehavioral development.
Superimposed pre-eclampsia (vs. chronic hypertension alone) has no adverse effect on (or
slightly better) intellectual development of the offspring; however, there is no information about
the antihypertensives received by the mothers during pregnancy [3]. For children born SGA,
neurodevelopmental outcomes are improved if the mother develops pregnancy hypertension
[102].
HDPs, and their treatment with antihypertensives, may predict generally modest long-term effects
on child development; clinicians should be aware of these mild disabilities and be prepared for early
school-age interventions. For example, in one study, methyldopa (but not labetalol) may be associated
with lower IQ, the duration of treatment being an independent negative predictor of children's per-
formance IQ [3].
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Practice points
Communities need to mobilise around the topics of pregnancy and its complications.
Women, and not girls, need to enter pregnancy when they are well nourished and at a time of
their choice.
Women require access to fully staffed and well-resourced health facilities.
Women should be screened for the HDPs, including pre-disease screening of risk.
Women with an HDP should receive personalised time-of-disease risk assessment.
All women with severe pregnancy hypertension should receive antihypertensive therapy,
whether pregnant or postpartum.
All women with non-severe pregnancy hypertension should have their BP normalised.
Magnesium sulphate is the agent of choice for the prevention and treatment of eclampsia as
well as for foetal neuroprotection.
Decisions about delivery are dependent on gestational age.
Vaginal delivery should always be considered.
Women with any HDP, and their offspring, are at increased risk for premature cardiovascular
disease.
Research agenda
Population-level estimates of the incidence and impact of the HDPs on pregnancies.
Populations' and decision-makers’ understanding of the HDPs to aid in identifying barriers and
facilitators for future interventions.
Evaluation of the use of biomarkers, such as placental growth factor and glycosylated fibro-
nectin, to screen populations of pregnant women at increased risk for pre-eclampsia and other
placental complications of pregnancy in those requiring the Edinburghmodel of antenatal care
and those for whom the four-visit model will suffice.
Identification of optimal antihypertensive to use in the setting of severe pregnancy hyperten-
sion will reduce the avoidable burden of HDP-related strokes.
Adequately powered and well-designed studies of both reduced-dosing regimens and com-
munity administration of magnesium sulphate.
Optimal timing of delivery for pregnant women with chronic hypertension.
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